Monday, December 22, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Barclays Analyst Reiterates Underweight Rating on ZimVie with Revised Price Target

Elaine Mendonca by Elaine Mendonca
March 5, 2024
in Breaking News
0
Redefining Success: How Franchises Adapt to Economic Shifts and Market Demands
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

Barclays analyst Matt Miksic has reiterated his Underweight rating on ZimVie (NASDAQ: ZIMV) with a revised price target. The new target is set at $16, up from the previous $13. This adjustment reflects Miksic’s cautious perspective on the stock’s potential compared to its industry peers and market benchmarks.

Overall, ZimVie’s performance is expected to be subdued in the near term, according to Miksic’s analysis.

ZIMV Stock Shows Positive Momentum Near 52-Week Highs on March 5, 2024

On March 5, 2024, ZIMV stock showed positive momentum as it traded near the top of its 52-week range and above its 200-day simple moving average. This indicates that the stock has been performing well in the long term and is currently in an upward trend.

The price of ZIMV shares increased by $0.22 since the market last closed, representing a 1.30% rise. The stock closed at $17.15, showing a strong performance for the day. Despite this increase, the stock remained unchanged in after-hours trading, suggesting that investors are still evaluating the stock’s potential.

Overall, ZIMV’s performance on March 5, 2024, was positive, with the stock showing price momentum and trading near its highest levels in the past year. Investors may be optimistic about the company’s future prospects, leading to increased interest and trading activity in the stock.

ZIMV Stock Reports Mixed Performances for 2024: Revenue and Net Income Decline

On March 5, 2024, ZIMV stock experienced mixed performances as the company reported its financial results for the past year and the fourth quarter. According to data from CNN Money, ZIMV’s total revenue for the past year was $457.43 million, which decreased by 49.95% compared to the previous year. The total revenue for the fourth quarter was $113.07 million, which remained flat compared to the previous quarter.

In terms of net income, ZIMV reported a net loss of $393.28 million for the past year, which represents a significant decrease of 515.65% compared to the previous year. However, the net loss for the fourth quarter improved slightly to -$22.16 million, showing a 0.0% increase compared to the previous quarter.

Earnings per share (EPS) for ZIMV also showed a decline over the past year and the fourth quarter. The EPS for the past year was reported at -$14.87, which decreased by 507.02% compared to the previous year. The EPS for the fourth quarter was -$12.37, showing a significant decrease of 6347.91% compared to the previous quarter.

Overall, the financial performance of ZIMV on March 5, 2024, reflected a challenging year for the company with significant declines in total revenue, net income, and earnings per share. Investors and analysts will be closely monitoring the company’s future strategies and initiatives to improve its financial performance and drive growth in the coming quarters.

Tags: ZIMV
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_Investment (5)

UBS Analyst Remains Bullish on Redwood Trust with Adjusted Price Target

5G Network

From 4G to 5G: How Airports Are Embracing Next-Generation Mobile Infrastructure

Finance_Budgeting (1)

Analyst Projections and Ratings for bluebird bio NASDAQ BLUE

Recommended

Tilray Stock

Tilray Faces Regulatory Hurdles as U.S. Policy Shifts Threaten Growth Strategy

1 month ago
Tesla Stock

Tesla Shares Surge as Musk Makes Largest-Ever Personal Investment

3 months ago
Ethereum Stock

Ethereum’s Fate Hinges on Federal Reserve Chair’s Upcoming Speech

4 months ago
Nvidia Stock

Nvidia Stock: AI Healthcare Investments Drive Record Highs

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Bitcoin Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Adobe’s Strategic Countermove in the AI Video Arena

Alphabet’s AI Strategy Gains Momentum with New Model and Major Deals

Tesla’s Valuation Faces Crucial Test Amid Legal Victory and Robotaxi Push

Wolfspeed Secures Financial and Strategic Milestones

Textron Stock Approaches Annual Peak Amid Strategic Wins

Intellia Therapeutics Faces Mounting Analyst Scrutiny Amid Regulatory Setback

Trending

Pfizer Stock
Analysis

Pfizer Shares Face a Multifaceted Squeeze

by Felix Baarz
December 22, 2025
0

The pharmaceutical giant Pfizer is navigating a challenging start to 2026, caught in a crossfire of financial,...

IonQ Stock

IonQ Secures Major European Contract Extension Valued at Over $60 Million

December 22, 2025
Lynas Stock

Lynas Gains Market Favor with Key Index Inclusion Amid Operational Hurdles

December 22, 2025
Adobe Stock

Adobe’s Strategic Countermove in the AI Video Arena

December 22, 2025
Alphabet Stock

Alphabet’s AI Strategy Gains Momentum with New Model and Major Deals

December 22, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Pfizer Shares Face a Multifaceted Squeeze
  • IonQ Secures Major European Contract Extension Valued at Over $60 Million
  • Lynas Gains Market Favor with Key Index Inclusion Amid Operational Hurdles

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com